PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
26.51%
Positive revenue growth while CRON.TO is negative. John Neff might see a notable competitive edge here.
674.09%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
92.54%
EBIT growth above 1.5x CRON.TO's 10.73%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
92.54%
Operating income growth above 1.5x CRON.TO's 0.64%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
89.98%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
90.72%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
90.72%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
6.68%
Slight or no buybacks while CRON.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
6.68%
Diluted share count expanding well above CRON.TO's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
334.00%
OCF growth under 50% of CRON.TO's 9288.52%. Michael Burry might suspect questionable revenue recognition or rising costs.
260.05%
FCF growth under 50% of CRON.TO's 3057.28%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
480.08%
5Y revenue/share CAGR above 1.5x CRON.TO's 276.82%. David Dodd would look for consistent product or market expansions fueling outperformance.
-38.62%
Negative 3Y CAGR while CRON.TO stands at 34.24%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1711.87%
10Y OCF/share CAGR above 1.5x CRON.TO's 580.04%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
360.13%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
543.04%
3Y OCF/share CAGR above 1.5x CRON.TO's 142.59%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-16516.68%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-737.15%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
38.51%
3Y net income/share CAGR 50-75% of CRON.TO's 61.47%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
5797.52%
10Y equity/share CAGR above 1.5x CRON.TO's 1384.78%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5.79%
Below 50% of CRON.TO's 314.22%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-7.21%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.06%
AR growth is negative/stable vs. CRON.TO's 121.43%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-1.11%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.57%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.38%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-2.25%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
5.26%
R&D dropping or stable vs. CRON.TO's 16.45%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
22.38%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.